INTRODUCTION: Antiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching >8 million individuals and reducing AIDS mortality and morbidity. Continued success of ART programs will require understanding the emergence of HIV drug resistance patterns among individuals in whom treatment has failed and managing ART from both an individual and public health perspective. We review data on the emergence of HIV drug resistance among individuals in whom first-line therapy has failed and clinical and resistance outcomes of those receiving second-line therapy in resource-limited settings. RESULTS: Resistance surveys among patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy suggest that 76%-90% of living patients achieve HIV RNA suppression by 12 months after ART initiation. Among patients with detectable HIV RNA at 12 months, HIV drug resistance, primarily due to M184V and NNRTI mutations, has been identified in 60%-72%, although the antiretroviral activity of proposed second-line regimens has been preserved. Complex mutation patterns, including thymidine-analog mutations, K65R, and multinucleoside mutations, are prevalent among cases of treatment failure identified by clinical or immunologic methods. Approximately 22% of patients receiving second-line therapy do not achieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving most failures. Major protease inhibitor resistance at the time of second-line failure ranges from 0% to 50%, but studies are limited. CONCLUSIONS: Resistance of HIV to first-line therapy is predictable at 12 months when evaluated by means of HIV RNA monitoring and, when detected, largely preserves second-line therapy options. Optimizing adherence, performing resistance surveillance, and improving treatment monitoring are critical for long-term prevention of drug resistance.
INTRODUCTION: Antiretroviral therapy (ART) in resource-limited settings has expanded in the last decade, reaching >8 million individuals and reducing AIDS mortality and morbidity. Continued success of ART programs will require understanding the emergence of HIV drug resistance patterns among individuals in whom treatment has failed and managing ART from both an individual and public health perspective. We review data on the emergence of HIV drug resistance among individuals in whom first-line therapy has failed and clinical and resistance outcomes of those receiving second-line therapy in resource-limited settings. RESULTS: Resistance surveys among patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy suggest that 76%-90% of living patients achieve HIV RNA suppression by 12 months after ART initiation. Among patients with detectable HIV RNA at 12 months, HIV drug resistance, primarily due to M184V and NNRTI mutations, has been identified in 60%-72%, although the antiretroviral activity of proposed second-line regimens has been preserved. Complex mutation patterns, including thymidine-analog mutations, K65R, and multinucleoside mutations, are prevalent among cases of treatment failure identified by clinical or immunologic methods. Approximately 22% of patients receiving second-line therapy do not achieve HIV RNA suppression by 6 months, with poor adherence, rather than HIV drug resistance, driving most failures. Major protease inhibitor resistance at the time of second-line failure ranges from 0% to 50%, but studies are limited. CONCLUSIONS: Resistance of HIV to first-line therapy is predictable at 12 months when evaluated by means of HIV RNA monitoring and, when detected, largely preserves second-line therapy options. Optimizing adherence, performing resistance surveillance, and improving treatment monitoring are critical for long-term prevention of drug resistance.
Entities:
Keywords:
antiretroviral drug resistance; resource-limited settings; second-line therapy
Authors: Lucile Larrouy; C Chazallon; R Landman; C Capitant; G Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; C Katlama; P M Girard; P Yeni; J P Aboulker; F Brun-Vezinet; D Descamps Journal: Antimicrob Agents Chemother Date: 2010-05-03 Impact factor: 5.191
Authors: Michele W Tang; Soo-Yon Rhee; Silvia Bertagnolio; Nathan Ford; Susan Holmes; Kim C Sigaloff; Raph L Hamers; Tobias F Rinke de Wit; Herve J Fleury; Phyllis J Kanki; Kiat Ruxrungtham; Claudia A Hawkins; Carole L Wallis; Wendy Stevens; Gert U van Zyl; Weerawat Manosuthi; Mina C Hosseinipour; Nicole Ngo-Giang-Huong; Laurent Belec; Martine Peeters; Avelin Aghokeng; Torsak Bunupuradah; Sherri Burda; Patricia Cane; Giulia Cappelli; Charlotte Charpentier; Anoumou Y Dagnra; Alaka K Deshpande; Ziad El-Katib; Susan H Eshleman; Joseph Fokam; Jean-Chrysostome Gody; David Katzenstein; Donato D Koyalta; Johnstone J Kumwenda; Marc Lallemant; Lutgarde Lynen; Vincent C Marconi; Nicolas A Margot; Sandrine Moussa; Thumbi Ndung'u; Phillipe N Nyambi; Catherine Orrell; Jonathan M Schapiro; Rob Schuurman; Sunee Sirivichayakul; Davey Smith; Maria Zolfo; Michael R Jordan; Robert W Shafer Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: Gert Uves van Zyl; Thijs E van Mens; Helen McIlleron; Michele Zeier; Jean B Nachega; Eric Decloedt; Carolina Malavazzi; Peter Smith; Yong Huang; Lize van der Merwe; Monica Gandhi; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2011-04 Impact factor: 3.731
Authors: Michael D Miller; Nicolas Margot; Biao Lu; Lijie Zhong; Shan-Shan Chen; Andrew Cheng; Michael Wulfsohn Journal: J Infect Dis Date: 2004-02-10 Impact factor: 5.226
Authors: Ravindra K Gupta; Michael R Jordan; Binta J Sultan; Andrew Hill; Daniel H J Davis; John Gregson; Anthony W Sawyer; Raph L Hamers; Nicaise Ndembi; Deenan Pillay; Silvia Bertagnolio Journal: Lancet Date: 2012-07-23 Impact factor: 79.321
Authors: K Brooks; A DeLong; M Balamane; L Schreier; M Orido; M Chepkenja; E Kemboi; M D'Antuono; P A Chan; W Emonyi; L Diero; M Coetzer; R Kantor Journal: J Clin Microbiol Date: 2015-11-11 Impact factor: 5.948
Authors: Emiko Urano; Uddhav Timilsina; Justin A Kaplan; Sherimay Ablan; Dibya Ghimire; Phuong Pham; Nishani Kuruppu; Rebecca Mandt; Stewart R Durell; Theodore J Nitz; David E Martin; Carl T Wild; Ritu Gaur; Eric O Freed Journal: J Virol Date: 2019-03-05 Impact factor: 5.103
Authors: Angelica N Martins; Abdul A Waheed; Sherimay D Ablan; Wei Huang; Alicia Newton; Christos J Petropoulos; Rodrigo D M Brindeiro; Eric O Freed Journal: J Virol Date: 2015-10-28 Impact factor: 5.103
Authors: Emiko Urano; Sherimay D Ablan; Rebecca Mandt; Gary T Pauly; Dina M Sigano; Joel P Schneider; David E Martin; Theodore J Nitz; Carl T Wild; Eric O Freed Journal: Antimicrob Agents Chemother Date: 2015-10-19 Impact factor: 5.191
Authors: Gert U van Zyl; Lisa M Frenkel; Michael H Chung; Wolfgang Preiser; John W Mellors; Jean B Nachega Journal: AIDS Date: 2014-11-28 Impact factor: 4.177